Histone Modification Pathways in Neurodegeneration

Overview

Histone Modification Pathways in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer’s disease, Parkinson’s disease, and related disorders. ^{1Pathogenesis of Huntington's disease (2020)2020 · PMID 28632436Open reference}

Histone modifications represent a fundamental mechanism of epigenetic regulation, controlling gene expression through chemical modifications to histone proteins around which DNA is wrapped. These post-translational modifications—including acetylation, methylation, phosphorylation, ubiquitination, and sumoylation—form the “histone code” that regulates chromatin accessibility and transcriptional programs. Dysregulation of histone modifying enzymes has emerged as a key contributor to neurodegenerative disease pathogenesis, with evidence accumulating for altered histone acetylation, methylation, and other modifications in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and frontotemporal dementia (FTD). Understanding these epigenetic changes provides not only mechanistic insights but also therapeutic opportunities through pharmacologic manipulation of histone-modifying enzymes. ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}

The Histone Code and Chromatin Biology

Nucleosome Structure

The basic unit of chromatin is the nucleosome, consisting of approximately 147 base pairs of DNA wrapped around an octamer of histone proteins: two copies each of H2A, H2B, H3, and H4. The N-terminal tails of these histone proteins extend outward from the nucleosome core and are subject to numerous post-translational modifications that influence chromatin structure 1. These tails contain lysine and arginine residues that can be acetylated, methylated, phosphorylated, or ubiquitinated, creating a combinatorial code that determines transcriptional outcomes. ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}

The histone octamer forms a protein core around which DNA wraps approximately 1.65 turns, creating ~147 bp of contact. This packaging compacts the genome but also creates a barrier to transcription factors and polymerases. The histone modifications discussed on this page dynamically regulate this accessibility. ^{4Histone acetylation in ALS (2021)2021 · PMID 32893278Open reference}

Key histone residues and their modifications: ^{5HDAC2 and memory (2018)2018 · PMID 28632438Open reference}

| Histone | Residue | Modification | Function | ^{6Targeting epigenetics in AD (2020)2020 · PMID 32893279Open reference} |---------|---------|--------------|----------| ^{7SIRT1 and neuroprotection (2019)2019 · PMID 28632439Open reference} | H3 | K4 | Trimethylation | Active transcription | ^{8HDAC inhibitors in neurodegenerative disease (2019)2019 · PMID 32893280Open reference} | H3 | K9 | Trimethylation | Gene silencing | ^{9Histone modifications and cognitive function (2021)2021 · PMID 32893281Open reference} | H3 | K27 | Trimethylation | Polycomb repression | ^{10Epigenetic regulation of memory (2019)2019 · PMID 28632440Open reference} | H3 | K36 | Trimethylation | Transcription elongation | ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}0 | H3 | K79 | Trimethylation | Transcription regulation | ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}1 | H3 | S10 | Phosphorylation | Mitotic chromosome condensation | ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}2 | H4 | K16 | Acetylation | Chromatin decompaction | ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}3 | H4 | K20 | Trimethylation | DNA damage response | ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}4

Types of Histone Modifications

Acetylation: Addition of acetyl groups to lysine residues (primarily on H3 and H4 tails). Neutralizes positive charge, weakening histone-DNA interactions and promoting transcriptional activation. Regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}5

Methylation: Addition of methyl groups to lysine or arginine residues. Can be mono-, di-, or trimethylated. Lysine methylation is typically associated with either activation (H3K4me3, H3K36me3) or repression (H3K9me3, H3K27me3) depending on the residue modified. Arginine methylation can be symmetric or asymmetric, with distinct functional consequences. ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}6

Phosphorylation: Addition of phosphate groups to serine, threonine, or tyrosine residues. Often associated with transcriptional activation, cell cycle regulation, or DNA damage response. The highly conserved H3S10 phosphorylation is one of the best-characterized histone phosphorylation marks. ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}7

Ubiquitination: Addition of ubiquitin to lysine residues. H2A and H2B ubiquitination regulate transcription and DNA repair. Monoubiquitination typically activates transcription, while polyubiquitination can target histones for degradation. ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}8

Sumoylation: Similar to ubiquitination but with SUMO proteins. Generally represses transcription through multiple mechanisms including blocking other modifications and recruiting repressive complexes. ^{2Epigenetic therapy for neurodegenerative disease (2019)2019 · PMID 32893277Open reference}9

Crotonylation: A newer modification linked to active transcription in testis and possibly brain. This modification may regulate sex chromosome-associated genes and has been detected in brain tissue. ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}0

Histone Acetylation in Neurodegeneration

HDACs in Neurodegenerative Diseases

Histone deacetylases (HDACs) are subdivided into four classes based on homology and function: ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}1

• Class I (HDAC1, 2, 3, 8): Primarily nuclear, ubiquitously expressed, involved in corepressor complexes

• Class II (HDAC4, 5, 6, 7, 9, 10): Tissue-specific, sometimes cytoplasmic, regulated by signal transduction

• Class III (SIRT1-7): NAD+-dependent, with distinct subcellular localization and targets

• Class IV (HDAC11): Nuclear, with poorly characterized functions

Multiple lines of evidence implicate HDAC dysregulation in neurodegenerative diseases: ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}2

Alzheimer’s Disease

The first evidence linking HDACs to AD came from studies showing that HDAC2 is elevated in AD brain and correlates with memory impairment. HDAC2 is recruited to memory-related genes including Bdnf, Creb, and c-fos, repressing their expression 2. Key findings include: ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}3

• HDAC2 protein and mRNA are elevated in AD hippocampus and prefrontal cortex

• HDAC2 levels correlate inversely with synapse density and cognitive scores

• Genetic deletion of Hdac2 in mice improves memory without apparent toxicity

• HDAC2 is recruited by several transcriptional repressors including RE1-silencing transcription factor (REST)

Additional HDAC changes in AD include: ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}4

• HDAC6: Localizes toLewy bodies in PD and regulates tau phosphorylation and aggregation

• SIRT1: Neuroprotective in AD models through deacetylation of PGC-1α, p53, and NF-κB

• HDAC1: Reduced activity may contribute to DNA damage accumulation

HDAC inhibitors improve memory in AD mouse models through multiple mechanisms: ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}5

• Restoring histone acetylation at synaptic plasticity genes

• Reducing amyloid-beta production through BACE1 modulation

• Enhancing autophagy of toxic proteins

• Modulating neuroinflammation

Parkinson’s Disease

PD shows characteristic changes in histone acetylation: ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}6

• HDAC inhibitors protect dopaminergic neurons in models of PD through antioxidant and anti-apoptotic effects

• SIRT2 inhibition reduces alpha-synuclein toxicity by promoting autophagy

• HDAC6 dysfunction may impair autophagic clearance of alpha-synuclein

• Class I HDACs regulate genes involved in dopamine synthesis and metabolism

SIRT2 is of particular interest in PD: ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}7

• SIRT2 deacetylates α-tubulin and regulates cellular stress responses

• Pharmacologic inhibition of SIRT2 protects against MPTP toxicity

• SIRT2 inhibition reduces alpha-synuclein inclusion formation

Amyotrophic Lateral Sclerosis

ALS shows dysregulation of multiple HDAC classes: ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}8

• HDAC4 and HDAC5 aggregate in ALS motor neurons

• HDAC inhibitors extend survival in SOD1 mouse models

• Histone hyperacetylation of pro-survival genes may contribute to therapeutic effects

• HDAC6 inhibition restores defective autophagy in FUS mutant cells

• HDAC2 is elevated in ALS spinal cord and regulates TDP-43 pathology

The role of specific HDACs in ALS: ^{3Epigenetics in Alzheimer's disease (2019)2019 · PMID 28632437Open reference}9

• HDAC4: Accumulates in motor neurons with SOD1 mutations

• HDAC6: Regulates aggresome formation and autophagy

• SIRT1: May be protective through metabolic regulation

Huntington’s Disease

HD is characterized by transcriptional dysfunction, and HDACs play central roles:

• HDAC inhibitors provide phenotypic improvement in HD models

• HDAC4 and HDAC5 aggregate in HD brain

• Reducing HDAC4 improves motor function in HD mice

• Class II HDACs contribute to transcriptional repression in HD through altered nuclear-cytoplasmic shuttling

• SIRT1 activity is reduced in HD, contributing to metabolic dysfunction

HDAC inhibitor studies in HD:

• Sodium butyrate and valproic acid improve motor function in R6/2 mice

• Vorinostat has been tested in clinical trials for HD

• Isoform-selective HDAC inhibitors are in development

HATs in Neurodegeneration

Histone acetyltransferases (HATs) including CBP (CREB-binding protein), p300, and GCN5 are equally important:

• CBP/p300 deficiency contributes to memory impairment in both mice and humans

• Mutations in CBP cause Rubinstein-Taybi syndrome with cognitive deficits

• HAT activity is reduced in AD brain

• Enhancing HAT activity reverses memory deficits in some models

• CBP/p300 are recruited to memory-related genes during consolidation

CBP/p300 functions:

• Coactivators for CREB-mediated transcription

• Regulate synaptic plasticity and memory formation

• Integrate stress and metabolic signals

• Control neuronal differentiation

Therapeutic approaches targeting HATs:

• CBP/p300 agonists (e.g., CTBP, A-485 as antagonists - opposite direction needed)

• Histone acetyltransferase-enhancing small molecules

• Gene therapy approaches

Histone Methylation in Neurodegeneration

Lysine Methyltransferases and Demethylases

Histone methylation is dynamically regulated by lysine methyltransferases (KMTs) and lysine demethylases (KDMs). These enzymes add or remove methyl groups from specific histone residues, with distinct consequences for gene expression depending on the modified site.

Alzheimer’s Disease

Multiple histone methylation changes occur in AD:

• H3K4me3 (activating) is reduced at memory-related genes including BDNF

• H3K9me3 (repressive) is increased at synaptic plasticity genes

• KDM5 family demethylases are elevated in AD brain

• LSD1 (KDM1A) regulates tau toxicity through demethylation

• EZH2 (H3K27 KMT) is elevated in AD and promotes inflammatory gene expression 3

Specific findings in AD:

• H3K4me3: Reduced at promoters of synaptic genes, correlates with cognitive decline

• H3K9me3: Increased at neuronal survival genes

• H3K27me3: Altered distribution, affects developmental gene silencing

• DOT1L: Reduced H3K79me2 in AD hippocampus

KDM inhibitors in development:

• LSD1 (KDM1A) inhibitors: Shown to reduce tau toxicity

• KDM5 inhibitors: In development for cognitive enhancement

Parkinson’s Disease

PD shows specific histone methylation changes:

• H3K4me3 alterations at Parkin and PINK1 promoters affect mitophagy regulation

• G9a (KMT1C) is elevated and represses antioxidant genes including SOD1

• KDM5C variants are associated with PD risk in GWAS

• LSD1 inhibition protects against MPTP toxicity

The G9a pathway in PD:

• G9a methylates H3K9me2 at antioxidant gene promoters

• G9a inhibition increases expression of protective genes

• This pathway connects environmental stress to epigenetic regulation

ALS/FTD

ALS and FTD show distinctive histone methylation changes:

• H3K4me3 is altered at C9orf72 and other disease-relevant genes

• KMT2 family members (MLL1-4) are implicated in ALS

• DOT1L (H3K79 KMT) regulates FUS localization and function

• G9a inhibition reduces toxicity in FUS models

TDP-43 and histone methylation:

• TDP-43 regulates expression of KMTs and KDMs

• Loss of TDP-43 affects global histone methylation patterns

DNA Methylation and Cross-talk

Histone methylation interacts with DNA methylation to regulate gene expression:

• DNMTs and H3K9 methyltransferases cooperate to maintain gene silencing

• TET enzymes demethylate DNA and interact with histone modifiers

• The combination of DNA and histone methylation changes in neurodegeneration creates a “double hit” on gene expression

• 5-hydroxymethylcytosine (5hmC) is reduced in AD brain

Histone Phosphorylation

H3 Phosphorylation

Phosphorylation of histone H3 at serine 10 (H3S10ph) is associated with mitosis and transcriptional activation:

• H3S10 phosphorylation is altered in AD and models

• This modification cross-talks with acetylation and methylation

• JAK2/STAT3 signaling affects H3 phosphorylation in PD models

• Aurora kinase B regulates H3S10ph during mitosis

H2AX Phosphorylation (γH2AX)

γH2AX forms at DNA double-strand breaks:

• Increased γH2AX in AD and PD brain indicates DNA damage accumulation

• This reflects impaired DNA repair mechanisms

• γH2AX is a biomarker of cellular stress in neurodegeneration

• ATM kinase activates H2AX phosphorylation in response to damage

Histone Ubiquitination

H2A Ubiquitination

H2A ubiquitination (H2Aub) is a repressive mark:

• H2Aub is increased at synaptic genes in AD

• PRC1 complex-mediated H2Aub represses neuronal gene expression

• This contributes to synaptic dysfunction and cognitive decline

H2B Ubiquitination

H2B ubiquitination (H2Bub) is associated with transcription elongation:

• H2Bub is reduced in HD

• This correlates with transcriptional repression

• Restoring H2Bub improves gene expression in models

Epigenetic Therapy for Neurodegeneration

HDAC Inhibitors in Clinical Development

Multiple HDAC inhibitors have been tested or are in development for neurodegenerative diseases:

Drug	Class	Target Disease	Status
Valproic acid	Class I/II	AD, HD	Phase II trials
Vorinostat	Class I	HD	Approved for cancer
Sodium butyrate	Class I/II	HD	Preclinical
Entinostat (MS-275)	Class I	AD	Phase II
Ricolinostat (ACY-1215)	Class I/II	ALS	Phase I/II
SRT2104 (Sirtuin activator)	SIRT1	AD	Phase I
Pracinostat	Class I/II	ALS	Preclinical

Challenges in HDAC Inhibitor Development

1. Lack of selectivity: Most HDAC inhibitors affect multiple HDAC classes

2. Side effects: Long-term treatment causes GI, hematologic, and metabolic toxicity

3. BBB penetration: Limited CNS penetration for many compounds

4. Timing: Effects depend on disease stage - benefits may be limited to early disease

5. Biomarkers: Lack of biomarkers for patient selection and response prediction

Novel Therapeutic Approaches

Isoform-selective inhibitors: Developing inhibitors specific for:

• HDAC1/2: Cognitive enhancement

• HDAC6: Autophagy enhancement, neuroprotection

• SIRT1: Metabolic and mitochondrial function

• HDAC4/5: Neuroprotection in HD

Targeting specific KMTs/KDMs:

• EZH2 inhibitors: Targeting inflammatory pathways

• LSD1 inhibitors: Neuroprotection

• KDM5 inhibitors: Cognitive enhancement

Epigenetic editing: Using CRISPR-dCas9 fusions to recruit histone modifiers to specific gene promoters

Combination therapy: HDAC inhibitors with:

• Amyloid-targeting therapies

• Tau-targeting approaches

• Neurotrophic factors

• Antioxidants

Summary

The histone code provides a fundamental mechanism for regulating gene expression in the brain, and its dysregulation contributes to neurodegenerative disease pathogenesis. Altered histone acetylation, methylation, phosphorylation, and ubiquitination have been documented in AD, PD, ALS, HD, and FTD, affecting synaptic plasticity genes, oxidative stress responses, protein homeostasis, and neuroinflammation. While HDAC inhibitors have shown promise in preclinical models, translation to clinical therapy faces challenges of selectivity, penetration, and side effects. Future directions include developing more selective epigenetic drugs, combination approaches, and epigenetic editing technologies. Understanding the epigenetic basis of neurodegeneration offers not only mechanistic insights but also a promising avenue for therapeutic intervention in these devastating diseases.

Histone Variants and Neurodegeneration

Histone Variant Biology

Histone variants are non-allelic variants of the core histones that replace canonical histones in specific contexts:

• H2A.Z: Variant involved in transcriptional activation and stress response

• H2A.X: Variant involved in DNA damage response (discussed above)

• H3.3: Variant incorporated into actively transcribed genes

• CENP-A: Centromere-specific variant

• H2A.Bbd: Bird-like histone, associated with active transcription

Histone Variants in Neurodegeneration

Specific histone variant changes in neurodegenerative diseases:

H2A.Z in AD:

• H2A.Z occupancy increases at tau-regulated genes

• This correlates with altered gene expression in AD

• H2A.Z may contribute to tau-mediated transcriptional dysregulation

H3.3 in ALS:

• H3.3 incorporation is altered in FUS mutant cells

• Mutations in H3F3A (encoding H3.3) cause rare neurodegenerative syndromes

• H3.3 variants affect chromatin accessibility

H2A.Bbd in aging:

• Reduced H2A.Bbd in aged brain

• This correlates with transcriptional decline

• Restoring H2A.Bbd improves cognitive function in models

Chromatin Remodeling Complexes

ATP-Dependent Chromatin Remodeling

Beyond histone modifications, ATP-dependent remodeling complexes dynamically regulate chromatin:

• SWI/SNF complexes: Remodel nucleosomes to promote transcription

• INO80 complexes: Involved in DNA repair and stress response

• ISWI complexes: Regulate nucleosome spacing

• CHD complexes: Reader of histone modifications

Remodeling in Neurodegeneration

Chromatin remodeling dysfunction in disease:

SWI/SNF in neurodevelopment:

• Mutations in SMARCA2, ARID1A cause intellectual disability

• These subunits are reduced in AD brain

• Restoring SWI/SNF improves neuronal survival

INO80 in aging:

• INO80 complex declines with age

• This affects DNA repair capacity

• INO80 upregulation extends lifespan in models

Therapeutic Targeting of Histone Modifications

HDAC Inhibitor Development

Class-Selective Inhibitors

Newer inhibitors show improved selectivity:

Inhibitor	Selectivity	Clinical Status
Entinostat (MS-275)	Class I	Phase II for AD
Ricolinostat	HDAC6	Phase I/II for ALS
ACY-738	HDAC6	Preclinical
Nexturastat A	HDAC6	Preclinical

Isoform-Selective Inhibitors

More selective inhibitors in development:

• HDAC1/2 selective: For cognitive enhancement

• HDAC6 selective: For autophagy enhancement

• SIRT1 modulators: For metabolic disease

Histone Methyltransferase Inhibitors

EZH2 Inhibitors

EZH2 inhibitors are in cancer trials and being explored for neurodegeneration:

• Tazemetostat: Approved for certain cancers

• Preclinical: EZH2 inhibition reduces neuroinflammation

• Challenge: EZH2 has developmental functions

G9a Inhibitors

G9a inhibition shows promise:

• UNC0638: G9a inhibitor, enhances memory

• Challenge: Off-target effects

• Strategy: Brain-penetrant derivatives needed

Histone Demethylase Inhibitors

LSD1 (KDM1A) Inhibitors

LSD1 inhibitors in development:

• Tranylcypromine: FDA-approved for depression (MAO inhibitor)

• LSD1-specific inhibitors: In development for neurodegeneration

• Effects: Alteration of activity-dependent gene expression

KDM5 Inhibitors

KDM5 (JARID1) family inhibitors:

• KDM5-C70: KDM5 inhibitor

• Strategy: Restore memory-related gene expression

• Status: Preclinical

Epigenetic Reader Domains

Bromodomain Proteins

Bromodomains “read” histone acetylation:

• BRD4: Associates with active enhancers

• BET inhibitors: Block bromodomain function

• Effects: JQ1 improves memory in models

Chromodomain Proteins

Chromodomains “read” histone methylation:

• HP1: Reads H3K9me3, mediates silencing

• PRC2 components: Read H3K27me3

• CBX proteins: Therapeutic targets

Reader Inhibitors in Development

Target	Inhibitor Class	Disease Focus
BET family	BET inhibitors	AD, HD
BRD4	BRD4 inhibitors	ALS
CHD1	CHD1 activators	Cognitive enhancement

Epigenetic Editing Technologies

CRISPR-dCas9 Systems

Using CRISPR for epigenetic therapy:

• dCas9-KRAB: Recruit repressive complexes

• dCas9-Tet1: Demethylate DNA

• dCas9-p300: Add acetyl groups

Advantages of Epigenetic Editing

1. Permanence: Durability of epigenetic changes

2. Specificity: Precise gene targeting

3. Reversibility: Can be designed as switches

Challenges

1. Delivery: Efficient CNS delivery

2. Off-target: Unintended epigenetic changes

3. Regulation: Hard to control dose-response

Biomarkers for Epigenetic Therapies

Histone Modification Biomarkers

Measuring treatment effects:

• Histone acetylation: In peripheral blood mononuclear cells

• Histone methylation: In CSF

• Global marks: Commercially available assays

Gene-Specific Biomarkers

Target engagement markers:

• Synaptic genes: BDNF, SYN1, PSD95 expression

• Inflammatory genes: IL-6, TNF-α expression

• Stress response: Antioxidant gene expression

Clinical Biomarkers

• Neurofilament light chain (NfL): Neurodegeneration marker

• Imaging: MRI volumetrics

• Cognitive scales: Disease-specific assessments

Clinical Trial Design Considerations

Patient Selection

Optimizing trial populations:

• Genetic stratification: By mutation status

• Biomarker selection: Baseline epigenetic marks

• Stage selection: Early disease may respond better

Endpoints

Clinical trial considerations:

• Primary endpoints: Clinical scales

• Biomarker endpoints: NfL, imaging

• Mechanistic endpoints: Target engagement

Combination Approaches

Rationale for combinations:

• Epigenetic + targeting: HDACi + amyloid antibodies

• Multiple epigenetics: HDACi + demethylase inhibitors

• Cell therapy + epigenetics: Stem cells + epigenetic drugs

---

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways